Please assess the completion status of the following clinical trial:

Trial Title: Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years old~* Patients having PCI with stenting 24-48 hours prior randomization, for 1. Stable angina 2.Ischaemia in provocative test 3.Acute coronary syndrome (unstable angina or myocardial infarction)~* Written Informed consent~* Platelet reactivity units (PRU) (VerifyNow) \>230~Exclusion Criteria:~* A history of bleeding diathesis~* Chronic oral anticoagulation treatment~* Contraindications to antiplatelet therapy~* Known platelet function disorders~* PCI or coronary artery bypass surgery \< 3 months~* Unsuccessful PCI (residual stenosis \> 30% or flow \< Thrombolysis in myocardial infarction flow 3)~* Planned staged PCI in the next 60 days~* Hemodynamic instability~* Cancer or hemodialysis~* Platelet count \<100 000/ μL, hematocrit \<30%~* Creatinine clearance \<25 ml/min~* A life expectancy\<1 year, inability to give informed consent~* High likelihood of being unavailable for the Day 60 follow up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- prasugrel (Type: EXPERIMENTAL): prasugrel per os 10mg/day
- clopidogrel (Type: ACTIVE_COMPARATOR): clopidogrel per os 150mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).